Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Azitra Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06830863
- Locations
- πΊπΈ
Yale University School of Medicine, New Haven, Connecticut, United States
πΊπΈNYU Langone, New York, New York, United States
πΊπΈThe Ohio State University, Gahanna, Ohio, United States
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Azitra Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06137157
- Locations
- πΊπΈ
Stanford University, Palo Alto, California, United States
πΊπΈYale University, New Haven, Connecticut, United States
Study to Evaluate the Safety of ATR-04
- Conditions
- Epidermal Growth FactorPapulopustular Rosacea
- Interventions
- Other: Placebo
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Azitra Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04731259
- Locations
- πΊπΈ
RCTS, Inc., Irving, Texas, United States
Safety Study of AZT-04 for Cosmetic Use
- Conditions
- Study of Three Doses of AZT-04 for Skin Appearance
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Azitra Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03820076
- Locations
- πΊπΈ
RCTS, Inc., Irving, Texas, United States
News
Azitra Doses First Patient in Phase 1/2 Trial of Live Biotherapeutic for EGFR Inhibitor-Associated Rash
Azitra has dosed the first patient in its Phase 1/2 clinical trial of ATR04-484, a topically applied live biotherapeutic designed to treat EGFR inhibitor-associated rash affecting approximately 150,000 people annually in the U.S.
Azitra Advances Clinical Programs for Netherton Syndrome and EGFR Inhibitor-Associated Rash
Azitra has initiated a Phase 1b trial for ATR-12 in Netherton syndrome patients, with initial safety data expected in H1 2025 and topline results by year-end 2025.
Azitra Announces Positive Progress in Netherton Syndrome and EGFRi Rash Programs
Azitra dosed the first patient in its Phase 1b trial of ATR-12 for Netherton syndrome, a genetic skin disorder, marking a key milestone in the drug's development.
Azitra's ATR-04 Receives FDA Fast Track Designation for EGFRi-Associated Skin Rash
Azitra's ATR-04, a topical therapy for moderate to severe skin rash induced by EGFR inhibitors, has received FDA Fast Track designation.